Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!
Latest news and updates
DirectorsTalk interview: N4 Pharma making ‘considerable’ progress
With the release of the Company Report for 2020, N4 Pharma’s CEO, Nigel Theobald, has spoken to Directors Talk about the highlights of last year year. He provides an update on our new refined strategy [...]
Interview with IG UK
N4 Pharma's CEO, Nigel Theobald, has been interviewed by IG UK on the company's growth so far and some of the research we are currently working on. Watch the interview in full below.
Nuvec®’s potential in the fight for a vaccine against COVID-19
Our CEO, Nigel Theobald, has written an article for Drug Discovery Today about the emerging vaccine delivery systems for COVID-19. He talks about how functionalised silica nanoparticles, like Nuvec®, offer a potentially safe and effective [...]